IgGenix Announces Food Allergy Research Presentation at American Academy of Allergy, Asthma & Immunology Annual Meeting | national company
SOUTH SAN FRANCISCO, Calif.– (BUSINESS WIRE) – February 23, 2022–
IgGenix, Inc., a biotechnology company taking a breakthrough approach to directly alleviating allergic disease, today announced a poster presentation at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that will will be held February 25-28, 2022, in Phoenix, Arizona.
“IgGenix is deeply invested in transforming the approach to allergy treatment by leading the way in scientific research to understand allergy at the molecular level,” said IgGenix Co-Founder and Chief Technology Officer Derek Croote, Ph.D. “We look forward to reuniting with other leaders in the food allergy community and providing insight into how our research has the potential to revolutionize the standard of allergy care for millions. of people who suffer from allergic diseases, including myself.”
Food allergies affect approximately 32 million Americans and 200 million people worldwide, and their incidence is increasing. Every three minutes, someone goes to the emergency room with foodborne anaphylaxis. IgGenix is committed to developing safer treatments with faster onset of action and more sustained clinical response through monoclonal antibody re-engineering.
IgE-mediated Reactions and Anaphylaxis: New Mechanisms and Strategies for Therapeutic Intervention (485)
- Overview: Blood from highly allergic donors produces high affinity IgE antibodies against food and non-food allergens
- Date and time: Sunday, February 27, 4:45 p.m. – 6:15 p.m. MST
- Location: Convention Center, North Building, 100 Level, 120 Concourse; also available to virtual AAAAI Annual Meeting attendees via the Virtual Poster Room
The summary will also appear in the February 2022 issue of The Journal of Allergy and Clinical Immunology.
IgGenix is a privately held biotechnology company taking a breakthrough approach to directly relieve food allergies and other severe allergies by rearranging key antibodies involved in the allergic cascade. Based on the research of Stanford University Professors Stephen Quake, Kari Nadeau and Derek Croote, IgGenix isolates allergen-specific IgE antibodies and transforms them into IgG antibodies that mitigate and possibly prevent the allergic cascade. This new approach can prevent life-threatening allergic reactions, save lives and reduce the constant fear that plagues people with severe allergies. For more information, visit www.IgGenix.com.
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220223005191/en/
CONTACT: For investor inquiries:
For media inquiries:
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICALS CLINICAL TRIALS
SOURCE: IgGenix, Inc.
Copyright BusinessWire 2022.
PUBLISHED: 02/23/2022 09:00 AM / DISK: 02/23/2022 09:02 AM
Copyright BusinessWire 2022.